Author

M. Emmy M. Dolman

Observed names: Dolman, Emmy, Dolman, M. Emmy M., E.M. Dolman, Emmy Dolman, Emmy M Dolman, Emmy M. Dolman, Emmy M. Dolman (21786712), Emmy ME Dolman, M Dolman, M Emmy M Dolman, M. E. (Emmy) M. Dolman, M. E. M. Dolman, M. Emmy Dolman, M.E. (Emmy) M. Dolman, M.E.M. Dolman, M.Emmy M. Dolman, Me (emmy M Dolman

Institutions: UNSW Sydney, Children's Cancer Institute Australia, Princess Máxima Center

Observed institutions: Utrecht University, Amsterdam UMC Location University of Amsterdam, UNSW Sydney, Children's Cancer Institute Australia, Princess Máxima Center, Amsterdam University Medical Centers, University of Amsterdam

ORCID: 0000-0002-0567-5918

Observed ORCID: 0000-0002-0567-5918

OpenAlex ID: A5029913993

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

2015 · Thomas F Eleveld, Derek A Oldridge, et al. · Nature Genetics · 555

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

2020 · Marie Wong, Chelsea Mayoh, et al. · Nature Medicine · 389

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

2020 · Camilla Calandrini, Frans Schutgens, et al. · Nature Communications · 315

Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells☆

2010 · M.E.M. Dolman, S. Harmsen, et al. · Advanced Drug Delivery Reviews · 154

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets

2018 · Bieke Decaesteker, Geertrui Denecker, et al. · Nature Communications · 106

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

2020 · Sally L George, Federica Lorenzi, et al. · EBioMedicine · 80

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

2020 · Lucas Moreno, Giuseppe Barone, et al. · European Journal of Cancer · 74

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours

2013 · Laurel T. Bate-Eya, Marli E. Ebus, et al. · European Journal of Cancer · 73

The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia

2020 · Sanne Noort, Priscilla Wander, et al. · Haematologica · 67

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

2015 · M. Emmy M. Dolman, Evon Poon, et al. · Clinical Cancer Research · 66

Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors

2021 · Camilla Calandrini, Sander R. van Hooff, et al. · Cell Reports · 63

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition

2016 · Laurel T. Bate-Eya, Ilona J.M. den Hartog, et al. · Oncotarget · 63

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

2022 · Michael T. Meister, Marian J. A. Groot Koerkamp, et al. · EMBO Molecular Medicine · 57

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

2023 · Chelsea Mayoh, Jie Mao, et al. · Cancer Research · 56

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

2022 · Carolina Nunes, Lisa Depestel, et al. · Science Advances · 51

Characterization of drug-lysozyme conjugates by sheathless capillary electrophoresis–time-of-flight mass spectrometry

2011 · R. Haselberg, S. Harmsen, et al. · Analytica Chimica Acta · 45

Epac-Rap Signaling Reduces Oxidative Stress in the Tubular Epithelium

2014 · Geurt Stokman, Yu Qin, et al. · Journal of the American Society of Nephrology · 39

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies

2021 · Waleed M. Kholosy, Marc Derieppe, et al. · Journal of Personalized Medicine · 38

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

2018 · Shima Gholizadeh, Emmy M. Dolman, et al. · Pharmaceutical Research · 35

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

2017 · Laurel T. Bate-Eya, Hinco J. Gierman, et al. · European Journal of Cancer · 35

Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases

2011 · M.E.M. Dolman, K.M.A. van Dorenmalen, et al. · Journal of Controlled Release · 34

Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma

2021 · Marlinde L. van den Boogaard, Rurika Oka, et al. · Proceedings of the National Academy of Sciences · 29

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells

2015 · M. Emmy M. Dolman, Ida van der Ploeg, et al. · PLoS ONE · 29

Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors

2008 · Marjan M. Fretz, M.E. (Emmy) M. Dolman, et al. · Journal of Controlled Release · 25

ALK positively regulates MYCN activity through repression of HBP1 expression

2018 · Shana Claeys, Geertrui Denecker, et al. · Oncogene · 24

Works count: 138

Citation count: 2,841

H-index: 24

I10-index: 41